Vanguard Group’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $468K | Buy |
292,753
+100,628
| +52% | +$208K | ﹤0.01% | 3951 |
|
|
2025
Q3 | $492K | Buy |
192,125
+173,301
| +921% | +$546K | ﹤0.01% | 3952 |
|
|
2025
Q2 | $34.1K | Hold |
18,824
| – | – | ﹤0.01% | 4218 |
|
|
2025
Q1 | $38.2K | Sell |
18,824
-55,393
| -75% | -$207K | ﹤0.01% | 4211 |
|
|
2024
Q4 | $444K | Sell |
74,217
-869
| -1% | -$7.26K | ﹤0.01% | 3972 |
|
|
2024
Q3 | $733K | Buy |
75,086
+14,434
| +24% | +$194K | ﹤0.01% | 3864 |
|
|
2024
Q2 | $1.24M | Sell |
60,652
-8,059
| -12% | -$270K | ﹤0.01% | 3719 |
|
|
2024
Q1 | $3.1M | Buy |
68,711
+620
| +0.9% | +$29.6K | ﹤0.01% | 3453 |
|
|
2023
Q4 | $3.21M | Sell |
68,091
-8,192
| -11% | -$455K | ﹤0.01% | 3440 |
|
|
2023
Q3 | $3.09M | Buy |
76,283
+5,738
| +8% | +$580K | ﹤0.01% | 3443 |
|
|
2023
Q2 | $7.52M | Buy |
70,545
+4,047
| +6% | +$1.35M | ﹤0.01% | 3110 |
|
|
2023
Q1 | $19.9M | Buy |
66,498
+1,235
| +2% | +$527K | ﹤0.01% | 2586 |
|
|
2022
Q4 | $22.4M | Buy |
65,263
+877
| +1% | +$212K | ﹤0.01% | 2568 |
|
|
2022
Q3 | $12.2M | Buy |
64,386
+2,165
| +3% | +$503K | ﹤0.01% | 2855 |
|
|
2022
Q2 | $13.1M | Sell |
62,221
-4,000
| -6% | -$841K | ﹤0.01% | 2842 |
|
|
2022
Q1 | $22.2M | Buy |
66,221
+2,325
| +4% | +$674K | ﹤0.01% | 2708 |
|
|
2021
Q4 | $20.8M | Buy |
63,896
+3,401
| +6% | +$1.46M | ﹤0.01% | 2822 |
|
|
2021
Q3 | $29.4M | Buy |
60,495
+4,080
| +7% | +$1.79M | ﹤0.01% | 2652 |
|
|
2021
Q2 | $26.2M | Buy |
56,415
+7,075
| +14% | +$3.86M | ﹤0.01% | 2708 |
|
|
2021
Q1 | $34.1M | Sell |
49,340
-7,459
| -13% | -$6M | ﹤0.01% | 2516 |
|
|
2020
Q4 | $42M | Buy |
56,799
+2,353
| +4% | +$1.83M | ﹤0.01% | 2292 |
|
|
2020
Q3 | $37.8M | Buy |
54,446
+18,409
| +51% | +$13.8M | ﹤0.01% | 2153 |
|
|
2020
Q2 | $30.6M | Buy |
36,037
+5,376
| +18% | +$3.51M | ﹤0.01% | 2228 |
|
|
2020
Q1 | $11M | Buy |
30,661
+6,434
| +27% | +$2.31M | ﹤0.01% | 2575 |
|
|
2019
Q4 | $5.66M | Buy |
24,227
+285
| +1% | +$28.7K | ﹤0.01% | 3130 |
|
|
2019
Q3 | $2.7M | Buy |
23,942
+7,736
| +48% | +$1.22M | ﹤0.01% | 3348 |
|
|
2019
Q2 | $2.84M | Buy |
16,206
+5,060
| +45% | +$857K | ﹤0.01% | 3367 |
|
|
2019
Q1 | $1.76M | Buy |
11,146
+7,505
| +206% | +$925K | ﹤0.01% | 3493 |
|
|
2018
Q4 | $224K | Sell |
3,641
-14,874
| -80% | -$1.25M | ﹤0.01% | 3883 |
|
|
2018
Q3 | $2.27M | Sell |
18,515
-285
| -2% | -$42.3K | ﹤0.01% | 3486 |
|
|
2018
Q2 | $2.77M | Buy |
18,800
+362
| +2% | +$55.2K | ﹤0.01% | 3401 |
|
|
2018
Q1 | $3.02M | Buy |
+18,438
| New | +$3.08M | ﹤0.01% | 3324 |
|
Other funds holding BTAI
OCM
GCP
Vanguard Group's BTAI Position: Q4 2025 in Review
Vanguard Group increased its BioXcel Therapeutics (BTAI) stake by 52% in Q4 2025, buying an estimated $208K and bringing the position to 292,753 shares worth $468K. The position accounts for ﹤0.01% of the portfolio, ranked #3951.
Vanguard Group first reported a position in BTAI in Q1 2018 and has held it in 32 quarters since. The position peaked at $42M in Q4 2020. 41 funds tracked by Wall St. Rank hold BTAI as of Q4 2025.
- Vanguard Group held 292,753 shares of BioXcel Therapeutics worth $468K as of Q4 2025.
- Vanguard Group bought 100,628 BioXcel Therapeutics shares in Q4 2025, an estimated $208K.
- BioXcel Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3951 holding.
- Vanguard Group first reported a position in BioXcel Therapeutics in Q1 2018 and has held it in 32 quarters since.
- Vanguard Group's BioXcel Therapeutics position peaked at $42M in Q4 2020.
- 41 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.